A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study

References

• CDC. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. CDC Fast Facts on Diabetes. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf [Last accessed 31 January 2014]
   Google Scholar
• Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-41
   PubMed Web of Science ®Google Scholar
• Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006;332:73-8
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• MHRA. Glitazones for diabetes. MHRA Product-Specific Information and Advice. London: Medicines and Healthcare Products Regulatory Agency, 2007. Available at: www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-G-L/glitazonesfordiabetes [Last accessed 3 February 2014]
   Google Scholar
• Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
   PubMed Web of Science ®Google Scholar
• Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-18
   PubMed Web of Science ®Google Scholar
• Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Ferrara A, Lewis JD, Quesenberry CP Jr, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011;34:923-9
   PubMed Web of Science ®Google Scholar
• Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone. Diabetes Care 2011;34:916-22
   PubMed Web of Science ®Google Scholar
• Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012;55:1953-62
   PubMed Web of Science ®Google Scholar
• Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case–control study. BMJ 2012;344:e3645
   PubMed Web of Science ®Google Scholar
• Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 2013;75:254-9
   PubMed Web of Science ®Google Scholar
• Currie CJ, Johnson JA. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab 2012;14:1-4
   PubMed Web of Science ®Google Scholar
• Conway BN, May ME, Signorello LB, Blot WJ. Mortality experience of a low-income population with young-onset diabetes. Diabetes Care 2012;35:542-8
   PubMed Web of Science ®Google Scholar
• Gamble JM, Simpson SH, Eurich DT, et al. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab 2010;12:47-53
   PubMed Web of Science ®Google Scholar
• Bolliger D, Seeberger MD, Lurati Buse G, et al. The influence of pre-admission hypoglycaemic therapy on cardiac morbidity and mortality in type 2 diabetic patients undergoing major non-cardiac surgery: a prospective observational study. Anaesthesia 2012;67:149-57
   PubMed Web of Science ®Google Scholar
• MacDonald MR, Eurich DT, Majumdar SR, et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case–control study from the U.K. General Practice Research Database. Diabetes Care 2010;33:1213-18
   PubMed Web of Science ®Google Scholar
• Vincent JL, Preiser JC, Sprung CL, et al. Insulin-treated diabetes is not associated with increased mortality in critically ill patients. Crit Care 2010;14:R12
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-28
   PubMed Web of Science ®Google Scholar
• Vallarino C, Perez A, Fusco G, et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints using propensity score weights. Clin Drug Investig 2013;33:621-31
   PubMed Web of Science ®Google Scholar
• Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999;150:327-33
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
   Web of Science ®Google Scholar
• Howden L, Meyer J. Age and sex composition: 2010. US Census Briefs. Washington, DC: US Department of Commerce, Economics and Statistics Administration, US Census Bureau, 2011. Available at: www.census.gov/prod/cen2010/briefs/c2010br-03.pdf [Last accessed 26 June 2012]
   Google Scholar
• Vaccaro O, Eberly LE, Neaton JD, et al. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med 2004;164:1438-43
   PubMed Web of Science ®Google Scholar
• Vallarino C, Perez A, Fusco G, et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig. 2013;33:621-31
   Google Scholar